Summary | |
---|---|
Symbol | DPYS |
Name | dihydropyrimidinase |
Aliases | DHPase; dihydropyrimidine amidohydrolase; hydantoinase |
Chromosomal Location | 8q22 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway |
Subcellular Location | - |
Domain |
PF01979 Amidohydrolase family |
Function |
Catalyzes the second step of the reductive pyrimidine degradation, the reversible hydrolytic ring opening of dihydropyrimidines. Can catalyze the ring opening of 5,6-dihydrouracil to N-carbamyl-alanine and of 5,6-dihydrothymine to N-carbamyl-amino isobutyrate. |
Biological Process |
GO:0006206 pyrimidine nucleobase metabolic process GO:0006208 pyrimidine nucleobase catabolic process GO:0006210 thymine catabolic process GO:0006212 uracil catabolic process GO:0006213 pyrimidine nucleoside metabolic process GO:0009112 nucleobase metabolic process GO:0009116 nucleoside metabolic process GO:0009164 nucleoside catabolic process GO:0019439 aromatic compound catabolic process GO:0019482 beta-alanine metabolic process GO:0019859 thymine metabolic process GO:0019860 uracil metabolic process GO:0034655 nucleobase-containing compound catabolic process GO:0044270 cellular nitrogen compound catabolic process GO:0046113 nucleobase catabolic process GO:0046135 pyrimidine nucleoside catabolic process GO:0046700 heterocycle catabolic process GO:0051259 protein oligomerization GO:0051260 protein homooligomerization GO:0051262 protein tetramerization GO:0051289 protein homotetramerization GO:0072527 pyrimidine-containing compound metabolic process GO:0072529 pyrimidine-containing compound catabolic process GO:1901136 carbohydrate derivative catabolic process GO:1901361 organic cyclic compound catabolic process GO:1901565 organonitrogen compound catabolic process GO:1901657 glycosyl compound metabolic process GO:1901658 glycosyl compound catabolic process |
Molecular Function |
GO:0002054 nucleobase binding GO:0002058 uracil binding GO:0002059 thymine binding GO:0002061 pyrimidine nucleobase binding GO:0004157 dihydropyrimidinase activity GO:0016597 amino acid binding GO:0016810 hydrolase activity, acting on carbon-nitrogen (but not peptide) bonds GO:0016812 hydrolase activity, acting on carbon-nitrogen (but not peptide) bonds, in cyclic amides GO:0031406 carboxylic acid binding GO:0043168 anion binding GO:0051219 phosphoprotein binding |
Cellular Component | - |
KEGG |
hsa00240 Pyrimidine metabolism hsa00410 beta-Alanine metabolism hsa00770 Pantothenate and CoA biosynthesis hsa00983 Drug metabolism - other enzymes hsa01100 Metabolic pathways |
Reactome |
R-HSA-1430728: Metabolism R-HSA-15869: Metabolism of nucleotides R-HSA-73621: Pyrimidine catabolism R-HSA-73848: Pyrimidine metabolism |
Summary | |
---|---|
Symbol | DPYS |
Name | dihydropyrimidinase |
Aliases | DHPase; dihydropyrimidine amidohydrolase; hydantoinase |
Chromosomal Location | 8q22 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Literatures that report relations between DPYS and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells. |
There is no record. |
Summary | |
---|---|
Symbol | DPYS |
Name | dihydropyrimidinase |
Aliases | DHPase; dihydropyrimidine amidohydrolase; hydantoinase |
Chromosomal Location | 8q22 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets. |
> High-throughput Screening
[ TOP ]
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Statistical results of DPYS in screening data sets for detecting immune reponses.
|
Summary | |
---|---|
Symbol | DPYS |
Name | dihydropyrimidinase |
Aliases | DHPase; dihydropyrimidine amidohydrolase; hydantoinase |
Chromosomal Location | 8q22 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders |
Points in the above scatter plot represent the expression difference of DPYS in various data sets.
|
Points in the above scatter plot represent the mutation difference of DPYS in various data sets.
|
Summary | |
---|---|
Symbol | DPYS |
Name | dihydropyrimidinase |
Aliases | DHPase; dihydropyrimidine amidohydrolase; hydantoinase |
Chromosomal Location | 8q22 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of DPYS. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene. |
Summary | |
---|---|
Symbol | DPYS |
Name | dihydropyrimidinase |
Aliases | DHPase; dihydropyrimidine amidohydrolase; hydantoinase |
Chromosomal Location | 8q22 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of DPYS. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by DPYS. > Immunoinhibitor > Immunostimulator > MHC molecule |
Summary | |
---|---|
Symbol | DPYS |
Name | dihydropyrimidinase |
Aliases | DHPase; dihydropyrimidine amidohydrolase; hydantoinase |
Chromosomal Location | 8q22 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of DPYS. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor |
Summary | |
---|---|
Symbol | DPYS |
Name | dihydropyrimidinase |
Aliases | DHPase; dihydropyrimidine amidohydrolase; hydantoinase |
Chromosomal Location | 8q22 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Distribution of DPYS expression across immune and molecular subtypes. > Immune subtype > Molecular subtype |
Summary | |
---|---|
Symbol | DPYS |
Name | dihydropyrimidinase |
Aliases | DHPase; dihydropyrimidine amidohydrolase; hydantoinase |
Chromosomal Location | 8q22 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Associations between DPYS and clinical features. > Overall survival analysis > Cancer stage > Tumor grade |